Vetoquinol SA

Paris Stock Exchange VETO.PA

Vetoquinol SA Total Non-Current Liabilities for the year ending December 31, 2023: USD 28.40 M

Vetoquinol SA Total Non-Current Liabilities is USD 28.40 M for the year ending December 31, 2023, a -0.94% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Vetoquinol SA Total Non-Current Liabilities for the year ending December 31, 2022 was USD 28.67 M, a -4.73% change year over year.
Vetoquinol SA Total Non-Current Liabilities for the year ending December 31, 2021 was USD 30.10 M, a -29.02% change year over year.
Vetoquinol SA Total Non-Current Liabilities for the year ending December 31, 2020 was USD 42.40 M, a 13,541.08% change year over year.
Vetoquinol SA Total Non-Current Liabilities for the year ending December 31, 2019 was USD 310.86 K, a 38.58% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Paris Stock Exchange: VETO.PA

Vetoquinol SA

CEO	Mr. Alain Masson
IPO Date	Nov. 17, 2006
Location	France
Headquarters	Magny-Vernois
Employees	2,519
Sector	Consumers Staples
Industries Pet Food Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pharmaceuticals Vaccines

Description

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

Key trends

Past 5 years